The goal of our study was to evaluate the effects of the specific HDAC1 and 3 inhibitor RGFP109 in an unbiased approach on the genome-wide transcriptional dysregulation and on the phenotypic deficits in HD mice using the R6/1 model. The gene discussed is HDAC1; the disease is Huntington disease.